Drug
Bgm1812
Bgm1812: highest development phase Phase 1, developed by BrightGene Bio-Medical Technology Co., Ltd.. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- BrightGene Bio-Medical Technology Co., Ltd.
Trials
| Drug | Phase | Indication |
|---|---|---|
| BGM1812 NCT07224399 | Phase 1 | Healhty |
Latest
No recent events.
Follow Bgm1812 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.